X

Drug Profile

SKF 107260

Latest Information Update: 21 Jan 2008

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Class Anticoagulants; Antiplatelets; Vascular disorder therapies
Mechanism of Action GPIIb-IIIa antagonists; Integrin alphaVbeta3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
11 Jan 2000 A preclinical study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
25 Nov 1998 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com